Novo Nordisk's Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B

Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use/CHMP adopted a positive opinion, recommending an expansion of the Alhemo (concizumab) label.

This recommendation includes the treatment of severe haemophilia A and moderate or severe haemophilia B in patients without inhibitors. If approved by the European Commission/EC, Alhemo, which is administered via a pen-injector device, will become available to all adult and paediatric patients aged 12 years and older living with these conditions.

The positive CHMP opinion is based on results from the Phase 3 explorer8 trial. This study met its primary endpoint and showed that Alhemo prophylaxis reduced spontaneous and traumatic bleeds for patients with haemophilia A and B without inhibitors compared to no prophylaxis. Specifically, Alhemo prophylaxis led to an 86% reduction in treated spontaneous and traumatic bleeds for haemophilia A patients without inhibitors, and a 79% reduction for haemophilia B patients without inhibitors.

Novo Nordisk (NYSE:NVO) researches, develops, manufactures, and distributes pharmaceutical products internationally and operates in two segments: Diabetes & Obesity Care and Rare Disease.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.